<DOC>
	<DOCNO>NCT02871362</DOCNO>
	<brief_summary>The purpose study evaluate benefit tolerability IQP-AS-118 systolic diastolic blood pressure ( BP ) explore effect parameter lipid metabolism subject elevate BP low density lipoprotein cholesterol ( LDL-C ) level pilot study .</brief_summary>
	<brief_title>Benefit IQP-AS-118 Blood Pressure LDL-cholesterol</brief_title>
	<detailed_description />
	<criteria>1 . Caucasian male female , 1865 year age 2 . Body mass index ( BMI ) 18.529.9 kg/m2 3 . Generally good health , particular electrocardiogram ( ECG ) without pathological finding screen 4 . High normal BP level ( 130139 / 8589 ) 20 % randomized subject hypertension grade 1 ( 140159 / 9099 ) BP level 80 % randomized subject screen ( mean 2nd 3rd measurement assessment triplicate screening ) baseline ( mean 2nd 3rd measurement assessment triplicate week 0 ) 5 . LDLC 100159 mg/dL 6 . Readiness comply study procedure , particular : Consumption IP entire study Maintaining habitual diet , exception consumption maximal 2 garlic clove per week Accepting blood draw Complying requirement BP measurement ( avoid strenuous exercise stimulant ( alcohol , caffeine ) least 24 h measurement ; refrain extreme cold heat exposure food fluid intake least 1 h measurement ) Filling health questionnaire 7 . Nonsmoker / smoke cessation last ≥12 month prior screen 8 . Stable body weight last 3 month prior screen ( &lt; 3 kg selfreported change ) 9 . If allow concomitant medication take must stable least last month prior screen 10 . Women childbearing potential : 1. negative pregnancy test ( ßHCG urine screen ) 2. commitment use reliable contraception method entire study Participation base upon write informed consent form ( ICF ) participant follow write oral information investigator regard nature , purpose , consequence possible risk clinical study . 1 . Known sensitivity component IP 2 . Clinically significant disturbance lipid metabolism 3 . Known genetic hyperlipidemia 4 . Known secondary hypertension 5 . Known whitecoat hypertension 6 . Known type1diabetes 7 . Uncontrolled within last 6 month prior screen diagnose type2diabetes 8 . Untreated nonstabilized thyroid disorder 9 . History and/or presence clinically significant cardiovascular disease per investigator 's judgement : 1 . Known congenital heart defect 2 . Myocardial infarction , heart failure , angina pectoris , lifethreatening arrhythmia stroke within last 6 month prior screen 3 . Existing thrombosis disposition thrombosis 10 . Any known significant serious condition / disease render subject ineligible , e.g . : 1 . History malignancy within past 5 year prior screen 2 . Bleeding disorder and/or need anticoagulant ( antiplatelet agent allow ) 3 . Current psychiatric care and/or use neuroleptic 4 . Bariatric surgery last 12 month prior screen 11 . Any known metabolic disease , gastrointestinal disorder clinically significant disease/disorder investigator 's opinion could interfere result study safety subject 12 . Known arm lymphedema ( e.g . due mastectomy ) 13 . Other clinically relevant excursion safety parameter and/or deviation &gt; 2 x ULN ( upper limit normal ) 14 . Dietary habit may interfere study objective : 1 . Eating disorder 2 . Subjects dietary restriction may affect study outcome 3 . Participation weight loss program 15 . Use drug supplement influence SBP DBP ( e.g . ACE inhibitor , diuretic , calcium channel ßblockers , grape seed extract , coenzyme Q10 etc . ) within last 4 week prior screen study 16 . Use lipid lower drug ( affect lipid metabolism , platelet function antioxidant status , etc . ) OR dietary health supplement ( e.g . omega3 fatty acid , green tea extract , calcium , red yeast rice , phytosterols ( incl . enrich product e.g . Becel ) , oat fiber , niacin , soy protein , psyllium seed husk , glucomannan , chitosan probiotics/prebiotics ) within last 4 week prior screen study 17 . Use drug influence cholesterol level ( e.g . corticosteroid , amiodarone , estrogen , anabolic steroid ) 18 . Use weight loss treatment 19 . Use recreational drug 20 . Alcohol abuse ( men : ≥21 units/week , woman : ≥14 units/ week ; 1 unit equal approximately 250 mL beer , 100 mL wine 35 mL spirit ) 21 . Women childbearing potential : pregnant breastfeed 22 . Participation another study blood donation last 30 day prior screen 23 . Any reason deem suitable exclusion per investigator 's judgment , e.g . : 1 . Insufficient compliance study procedures 2 . Inability communicate site study staff</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>